MooreKuehn.jpg
Moore Kuehn Encourages MTSC, SPRQ, NEOS, and PRSP Investors to Contact Law Firm
28 janv. 2021 11h04 HE | Moore Kuehn
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Neos Therapeutics, Inc. Merger
11 déc. 2020 10h38 HE | Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Neos Therapeutics, Inc. (“Neos”) (NASDAQ GS: NEOS) regarding possible breaches of...
Neos Therapeutics logo
Neos Therapeutics Announces Appointment of James Robinson to Board of Directors
30 janv. 2019 08h00 HE | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics logo
Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation
26 déc. 2018 07h30 HE | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Neos Therapeutics logo
Neos Therapeutics Announces Realignment of Commercial Organization
30 nov. 2018 07h30 HE | Neos Therapeutics, Inc.
– Strategic assessment leads to new salesforce structure and is expected to accelerate path to profitability –  – Company to host conference call today at 8:30am ET – DALLAS and FORT WORTH, Texas,...
Neos Therapeutics logo
Neos Therapeutics Reports Third Quarter 2018 Financial Results
09 nov. 2018 07h00 HE | Neos Therapeutics, Inc.
Company to host conference call today at 8:30am ET  DALLAS and FORT WORTH, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical...
Neos Therapeutics logo
Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
06 nov. 2018 09h21 HE | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and...
Neos Therapeutics logo
Neos Therapeutics Announces Proposed Offering of Common Stock
05 nov. 2018 16h03 HE | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and...
Neos Therapeutics logo
Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018
02 nov. 2018 07h30 HE | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the opening...
Neos Therapeutics logo
Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
24 oct. 2018 08h00 HE | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release...